Matches in DBpedia 2014 for { <http://dbpedia.org/resource/CP-809,101> ?p ?o. }
Showing items 1 to 37 of
37
with 100 items per page.
- CP-809,101 abstract "CP-809,101 is a drug which acts as a potent and selective 5-HT2C receptor agonist. It had promising results in animal models of obesity and psychosis, but associated with genotoxicity which means that future use will be restricted to scientific research applications only.".
- CP-809,101 atcPrefix "None".
- CP-809,101 casNumber "479683-64-2".
- CP-809,101 iupacName "2-[(3-Chlorophenyl)methoxy]-6-(1-piperazinyl)pyrazine".
- CP-809,101 thumbnail CP-809,101_structure.png?width=300.
- CP-809,101 wikiPageID "23998044".
- CP-809,101 wikiPageRevisionID "593867425".
- CP-809,101 atcPrefix "None".
- CP-809,101 c "15".
- CP-809,101 casNumber "479683".
- CP-809,101 cl "1".
- CP-809,101 h "17".
- CP-809,101 hasPhotoCollection CP-809,101.
- CP-809,101 iupacName "2".
- CP-809,101 molecularWeight "304.774".
- CP-809,101 n "4".
- CP-809,101 o "1".
- CP-809,101 smiles "C2CNCCN2ccncc3OCccccc1Cl".
- CP-809,101 verifiedrevid "451224368".
- CP-809,101 width "220".
- CP-809,101 subject Category:Organochlorides.
- CP-809,101 subject Category:Pfizer.
- CP-809,101 subject Category:Phenol_ethers.
- CP-809,101 subject Category:Piperazines.
- CP-809,101 subject Category:Pyrimidines.
- CP-809,101 subject Category:Serotonin_receptor_agonists.
- CP-809,101 type Drug.
- CP-809,101 type DrugProduct.
- CP-809,101 type FunctionalSubstance.
- CP-809,101 comment "CP-809,101 is a drug which acts as a potent and selective 5-HT2C receptor agonist. It had promising results in animal models of obesity and psychosis, but associated with genotoxicity which means that future use will be restricted to scientific research applications only.".
- CP-809,101 label "CP-809,101".
- CP-809,101 sameAs m.07kct93.
- CP-809,101 sameAs Q5013585.
- CP-809,101 sameAs Q5013585.
- CP-809,101 wasDerivedFrom CP-809,101?oldid=593867425.
- CP-809,101 depiction CP-809,101_structure.png.
- CP-809,101 isPrimaryTopicOf CP-809,101.
